OHSU Researchers Discover Breast Cancer Drug Palbociclib Overcomes Venetoclax Resistance in Acute Myeloid Leukemia
核心洞察
Oregon Health & Science University researchers identified a promising drug combination pairing venetoclax with palbociclib that produced significantly stronger anti-leukemia activity than venetoclax alone in over 300 AML patient samples.
The combination therapy overcomes drug resistance by blocking AML cells' adaptive protein production mechanisms, with mouse models showing survival extension to 11-12 months compared to no benefit from venetoclax alone.
Despite current venetoclax-azacitidine therapy improving initial response rates, AML's five-year survival rate remains only 25-40%, highlighting the critical need for resistance-overcoming treatments.
Oregon Health & Science University researchers have identified a breakthrough drug combination that could transform treatment for patients with acute myeloid leukemia (AML) who develop resistance to current frontline therapies. The study, published in Cell Reports Medicine, demonstrates that combining venetoclax with palbociclib—a breast cancer drug—produces significantly stronger and more durable anti-leukemia activity than venetoclax alone.
Novel Drug Combination Shows Superior Efficacy
The research team analyzed more than 300 AML patient samples and tested 25 different drug combinations. Venetoclax paired with palbociclib emerged as the most effective combination, prompting deeper investigation into its mechanisms of action. The findings were validated in both human tissue samples and mouse models carrying human leukemia cells.
"Of the 25 drug combinations tested, venetoclax plus palbociclib was the most effective. That really motivated us to dig deeper into why it works so well, and why it appears to overcome resistance seen with current therapy," said Melissa Stewart, Ph.D., research assistant professor in the OHSU School of Medicine and Knight Cancer Institute and lead author of the study.
Addressing Critical Treatment Resistance Challenge
More than 20,000 Americans are diagnosed with AML each year, making it one of the most common and aggressive forms of leukemia. Since receiving FDA approval in 2019, venetoclax combined with azacitidine has become a standard treatment for many AML patients. However, drug resistance remains a nearly universal problem that limits long-term survival.
"Unfortunately, almost everyone will eventually have drug resistance," explained Jeffrey Tyner, Ph.D., professor of cell, developmental and cancer biology in the OHSU School of Medicine and corresponding author of the study. "This regimen has improved initial response rates and quality of life, but the five-year survival rate for AML is still only about 25% to 40%. We have a lot of work to do."
Mechanism of Action Reveals Dual Pathway Targeting
The study uncovered the biological basis for the combination's effectiveness. AML cells exposed to venetoclax alone attempt to survive by increasing protein production. Palbociclib, originally approved for breast cancer treatment, blocks this adaptive response by regulating the protein-production machinery within cells.
"Patient samples that responded strongly to the combination showed clear downregulation of genes involved in protein synthesis," Stewart noted. "This was a big clue."
A genome-wide CRISPR screen provided additional insights, revealing that while venetoclax alone becomes more effective when protein-production genes are lost, the combination therapy operates independently of this vulnerability. This suggests the two drugs work synergistically to shut down multiple survival pathways.
Preclinical Models Demonstrate Dramatic Survival Benefits
The research team tested the combination using mouse models implanted with human AML cells carrying mutations known to cause venetoclax resistance. The results were striking: while venetoclax alone provided no survival benefit, the combination therapy extended survival dramatically.
"In this model, venetoclax alone didn't extend survival at all—just as we'd expect based on the genetics," Stewart explained. "But with the combination, the majority of mice lived 11 to 12 months. In fact, one mouse was still alive when the study ended."
Building on National AML Research Initiative
The study builds directly on the Beat AML 1.0 program, a national initiative aimed at transforming AML treatment. Tyner, a co-leader of this program, emphasized how the current research validates predictions from the larger dataset.
"This combination was nominated from the Beat AML data, and Dr. Stewart validated that prediction, showing not only that it works, but why," Tyner said.
Future Clinical Development Plans
The research team is already evaluating other drugs similar to palbociclib, many also approved for breast cancer, to expand future clinical trial options. The researchers are working toward moving the combination into clinical testing.
"We haven't tested it in patients yet, but based on everything we've seen, our prediction is that this combination would mitigate most known resistance mechanisms to the current standard therapy," Tyner stated. "Making it a clinical reality will take work, but this is exactly why we do what we do."
The researchers emphasized the importance of following scientific data across traditional cancer boundaries. "Some might ask why a breast cancer drug would work in AML," Tyner noted. "But biology can be shared across very different cancers. This is a great example of why keeping an open mind matters and following the data where it leads."